Opinion/Ideas: The Fall of Big Cap Biotech Stocks.


21-May-2018 16:49 PM



    The most talk about big-cap biotech falling is Celgene Corp (CELG) which is down -4.70% as of today closed. Celgene Corp (CELG) is 8.31% weight to iShares Nasdaq Biotechnology ETF (IBB). Additionally, the top ten holding in (IBB),  there are five other big-cap biotech stocks dropping more than 20% from their 52 week-highs. Here the top 10 weight in iShares Nasdaq Biotech ETF (IBB) and their performance.

          Company                                                  Weight %

  1. Celgene Corp (CELG)                                8.31%
  2. Amgen Inc (AMGN)                                   7.89%
  3. Biogen Inc (BIIB)                                        7.87%
  4. Gilead Sciences Inc (GILD)                       7.62%
  5. Vertex Pharmaceuticals Inc (VRTX)           5.38%
  6. Illumina Inc (ILMN)                                     4.39%
  7. Regeneron Pharmaceuticals (REGN)         3.94%
  8. Alexion Pharmaceuticals Inc (ALXN)           3.67%
  9. Mylan N.V. (MYL)                                         2.93%
  10. BioMarin Pharmaceuticals Inc (BMRN)        2.07%

    As for performance:  the iShares Nasdaq Biotechnology ETF (IBB) 3 months is down -3.61%, Year-To-Date down -0.37% and 1 month is up +1.35%. The best performance for this year big-cap biotech is Illumina Inc (ILMN), YTD up +22.79% and 1-year up +51.57%. The worse performance is Celgene Corp (CELG), YTD down -28.43%, 3-months down -21.59% and 1 year down -36.12%. Is this the buying opportunity time for CELG?

 Contact us:

Twitter: @BiotechMoney18






Add Your Comment

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.